POP Biotechnologies
Developer of a liposome-based nanoparticle platform that enables rapid generation of particleized vaccines and light-activated drug delivery. The company advances vaccine and therapeutic programs through a liposome platform that stably displays his-tagged antigens, co-delivers lipid adjuvants, supports multivalent antigen formulations, and enables light-triggered release of payloads for targeted chemotherapy. Activities include preclinical testing, GMP production of lipid components, and clinical trial participation.
Industries
Nr. of Employees
small (1-50)
POP Biotechnologies
Patents
Vaccine composition for chickenpox or Varicella Zoster and method of using same
US-12527859-B2
View Details
Vaccine composition for chickenpox or Varicella Zoster and method of using same
US-12527859-B2
View DetailsProducts
EuCorVac-19 (protein-based SARS-CoV-2 vaccine)
Protein antigen vaccine formulated using the particleized liposome platform; progressed through Phase I/II and Phase III clinical trials in partnership.
PhotoDOX (light-activated chemotherapy formulation)
Porphyrin-phospholipid nanoparticle combined with doxorubicin to enable red-light-triggered tumor ablation and localized drug release.
SNAP nanoparticle vaccine platform
Platform technology for rapid formation of antigen-displaying liposomes enabling multivalent and particleized vaccines.
EuCorVac-19 (protein-based SARS-CoV-2 vaccine)
Protein antigen vaccine formulated using the particleized liposome platform; progressed through Phase I/II and Phase III clinical trials in partnership.
PhotoDOX (light-activated chemotherapy formulation)
Porphyrin-phospholipid nanoparticle combined with doxorubicin to enable red-light-triggered tumor ablation and localized drug release.
SNAP nanoparticle vaccine platform
Platform technology for rapid formation of antigen-displaying liposomes enabling multivalent and particleized vaccines.
Services
Partnerships for platform application, technology transfer, and joint development of vaccines and therapeutics.
Preclinical evaluation services including tumor efficacy studies, pharmacokinetics, and GLP toxicology reporting.
Provision of GMP-produced lipid components and shipment of liposomes with instructions for collaborator particle formation.
Partnerships for platform application, technology transfer, and joint development of vaccines and therapeutics.
Preclinical evaluation services including tumor efficacy studies, pharmacokinetics, and GLP toxicology reporting.
Provision of GMP-produced lipid components and shipment of liposomes with instructions for collaborator particle formation.
Expertise Areas
- Particle-based vaccine platform development
- Liposome formulation and biomaterials
- Photodynamic light-activated drug delivery
- Preclinical testing and GLP toxicology
Key Technologies
- Porphyrin-phospholipid liposomes
- His-tag antigen membrane anchoring
- Particleized antigen display
- Adjuvant co-formulation (lipid adjuvants)
News & Updates
Awarded a $2.46M NIH grant to pursue development of a mosaic active immunotherapy against Alzheimer's disease.
Award of $1.5M from CEPI to advance the SNAP platform toward a vaccine for severe fever with thrombocytopenia syndrome (SFTS).
Announcement of a vaccine concept against H5N1 avian influenza.
Publication of interim safety and immunogenicity analysis for a SNAP-based COVID-19 vaccine in Journal of Medical Virology.
Received a $2.84M Phase II SBIR award from NIAID to advance a seasonal influenza vaccine approach.
Awarded a $2.46M NIH grant to pursue development of a mosaic active immunotherapy against Alzheimer's disease.
Award of $1.5M from CEPI to advance the SNAP platform toward a vaccine for severe fever with thrombocytopenia syndrome (SFTS).
Announcement of a vaccine concept against H5N1 avian influenza.
Publication of interim safety and immunogenicity analysis for a SNAP-based COVID-19 vaccine in Journal of Medical Virology.
Received a $2.84M Phase II SBIR award from NIAID to advance a seasonal influenza vaccine approach.